Claims
- 1. A purified mutant hIL13 molecule, wherein the molecule comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-9.
- 2. A purified mutant hIL13 molecule, wherein the molecule consists of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-9.
- 3. The purified mutant hIL13 molecule of claim 1, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO: 2.
- 4. The purified mutant hIL13 molecule of claim 1, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO: 3.
- 5. The purified mutant hIL13 molecule of claim 1, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO: 4.
- 6. The purified mutant hIL13 molecule of claim 1, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO: 5.
- 7. The purified mutant hIL13 molecule of claim 1, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO: 6.
- 8. The purified mutant hIL13 molecule of claim 1, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO: 7.
- 9. The purified mutant hIL13 molecule of claim 1, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO: 8.
- 10. The purified mutant hIL13 molecule of claim 1, wherein the molecule comprises a polypeptide having the amino acid sequence of SEQ ID NO: 9.
- 11. The purified mutant hIL13 molecule of claim 1, further comprising a pharmaceutically acceptable carrier.
- 12. The purified mutant hIL13 molecule of claim 2, further comprising a pharmaceutically acceptable carrier.
- 13. The purified mutant hIL13 molecule of claim 1, wherein the molecule is conjugated to an effector molecule selected from the group consisting of a cytotoxin, a detectable label, an antibody, a liposome, and a lipid.
- 14. The purified mutant hIL13 molecule of claim 2, wherein the molecule is conjugated to an effector molecule selected from the group consisting of a cytotoxin, a detectable label, an antibody, a liposome, and a lipid.
- 15. The purified mutant hIL13 molecule of claim 13, wherein the effector molecule is a cytotoxin selected from the group consisting of a Pseudomonas exotoxin, Diptheria toxin, ricin, abrin, saporin, and pokeweed viral protein.
- 16. The purified mutant hIL13 molecule of claim 15, wherein the cytotoxin is selected from the group consisting of PE38QQR, PE1E, and PE4E.
- 17. The purified mutant hIL13 molecule of claim 13, wherein the effector molecule comprises a radionuclide.
- 18. The purified mutant hIL13 molecule of claim 14, wherein the effector molecule is a cytotoxin selected from the group consisting of a Pseudomonas exotoxin, Diptheria toxin, ricin, abrin, saporin, and pokeweed viral protein.
- 19. The purified mutant hIL13molecule of claim 18, wherein the cytotoxin is selected from the group consisting of PE38QQR, PE1E, and PE4E.
- 20. The purified mutant hIL13 molecule of claim 14, wherein the effector molecule comprises a radionuclide.
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a continuation-in-part of U.S. patent application Ser. No. 09/054,711, now U.S. Pat. No. 6,296,843, filed on Apr. 3, 1998, and is related to and claims the benefit of U.S. Provisional patent application No. 60/229,194 filed Aug. 30, 2000.
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
This invention was made in part with U.S. government support under grant CA741145 awarded by the National Institutes of Health. The U.S. government may have certain rights in the invention.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5696234 |
Zurawski et al. |
Dec 1997 |
A |
6028176 |
Greve et al. |
Feb 2000 |
A |
6296843 |
Debinski |
Oct 2001 |
B1 |
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9604306 |
Feb 1996 |
WO |
Non-Patent Literature Citations (2)
Entry |
Pastan et al., Ann. Rev. Biochem. 1992, vol. 61, pp. 331-354).* |
Chaudhary et al. J. Biol. Chem., 1990, vol. 265, pp. 16306-16310). |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/229194 |
Aug 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/054711 |
Apr 1998 |
US |
Child |
09/938936 |
|
US |